JSH guidelines for the management of hepatitis C virus infection (ver 3; abstract)

Estimating the cost‐effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b

“…The combination of DCV + ASV has been shown to be efficacious and well tolerated in those with HCV genotype 1b infection, including both treatment‐naive and previously treated patients, as well as those who are intolerant of or ineligible for IFN‐based regimens . Based upon this, the DCV + ASV regimen has been incorporated into recent Japanese clinical guidelines …”